2020 ASCO Virtual Direct™ Highlights | San Francisco
The 2020 ASCO Virtual Direct™ Highlights condensed the most cutting-edge science and education from the world’s premier oncology event into a two-day virtual program. The abstracts chosen for presentation and discussion reflect the foremost research and strategies in oncology that directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment from a healthcare team perspective. Expert faculty placed abstract findings into clinical context and discuss how the results may change the current standard of care.
Get Started Now
Enroll in CourseLearning Objectives
Summarize the most significant advances presented at the 2020 ASCO Annual Meeting
Review the current standard of care for malignancies
Discuss controversies in the management of cancers
Accreditation Information
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 11.75 AMA PRA Category 1 CreditsTM for physicians and 11.75 contact hours for nurses and 11.75 of knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
How This Course Works
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
A link to the evaluation will be provided at the conclusion of the course.
If you have questions regarding this enduring material activity, please contact us at certificates@amedcoemail.com.
Frequently Asked Questions
How do I access my CME/CE Credits?
A link will be provided you to you at the conclusion of the course. You will be asked to fill out a brief evaluation and your certificate will be automatically emailed back to you.
How long do I have access to the course?
This CME course will be available to access until August 2023.
Can I have face to face interaction with Instructor?
No, this is an online self-paced course with video demonstration. However, you are free to connect with the medical experts for each session on social media or contact the team and we will connect you.
How many credits can I obtain?
Amedco LLC designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM for physicians and 11.75 contact hours for nurses and 11.75 of knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Course Curriculum
-
ASCO Virtual Direct™ Highlights San Francisco | Learners Notification
-
Gastrointestinal Cancers – Colorectal | Chloe Atreya, MD, PhD
-
Gastrointestinal Cancers – Non Colorectal | Kit Wong, MD
-
Melanoma | Kevin Kim, MD
-
Hematological Malignancies – Leukemia | Ravi Vij, MD, MBA
-
Hematological Malignancies – Lymphoma | David Maloney, MD, PhD
-
GYN Cancer | Oliver Dorigo, MD, PhD
-
Breast Cancer – Adjuvant | Mark Pegram, MD
-
Breast Cancer – Metastatic | Hope Rugo, MD
-
Genitourinary Cancers – Prostate | Hala Borno, MD
-
Genitourinary Cancers – Non Prostate | David Quinn, MD
-
Social Media | Deanna Attai, MD
-
Optimizing Therapy in HER2+ Disease | Hope S. Rugo, MD
-
Head and Neck | A. Dimitri Colevas, MD
-
Lung Cancer | Ravi Salgia, MD, PhD